{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:34:59Z","timestamp":1793129699825,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["journals.elsevierhealth.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Nuclear Cardiology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s12350-021-02806-4","type":"journal-article","created":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T18:32:17Z","timestamp":1633372337000},"page":"2679-2690","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Quantitative technetium pyrophosphate and cardiovascular magnetic resonance in patients with suspected cardiac amyloidosis"],"prefix":"10.1016","volume":"29","author":[{"given":"Golnaz","family":"Roshankar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geneva C.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Cadet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nowell M.","family":"Fine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Jimenez-Zepeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr J.","family":"Slomka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4676-2433","authenticated-orcid":false,"given":"Robert J.H.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s12350-021-02806-4_bib1","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s12350-021-02806-4_bib2","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"AL (light-chain) cardiac amyloidosis: A review of diagnosis and therapy","volume":"68","author":"Falk","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s12350-021-02806-4_bib3","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cardfail.2019.08.001","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging","volume":"25","author":"Dorbala","year":"2019","journal-title":"J Card Fail"},{"key":"10.1007\/s12350-021-02806-4_bib4","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/CIRCIMAGING.112.000132","article-title":"(99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses","volume":"6","author":"Bokhari","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1007\/s12350-021-02806-4_bib5","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s12350-020-02139-8","article-title":"Technetium pyrophosphate nuclear scintigraphy for cardiac amyloidosis: Imaging at 1 vs 3 hours and planar vs SPECT\/CT","volume":"27","author":"Sperry","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-021-02806-4_bib6","doi-asserted-by":"crossref","unstructured":"Miller R, Cadet S, Mah D, Pournazari P, Chan D, Fine N et al. Diagnostic and Prognostic Value of Technetium-99m Pyrophosphate Uptake Quantitation for Transthyretin Cardiac Amyloidosis. J Nucl Cardiol 2020 (In press).","DOI":"10.1007\/s12350-021-02563-4"},{"key":"10.1007\/s12350-021-02806-4_bib7","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1007\/s12350-019-01893-8","article-title":"Quantitative (99m)Tc-DPD SPECT\/CT in patients with suspected ATTR cardiac amyloidosis: Feasibility and correlation with visual scores","volume":"27","author":"Caobelli","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-021-02806-4_bib8","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1007\/s12350-019-01935-1","article-title":"The current status of quantitative SPECT\/CT in the assessment of transthyretin cardiac amyloidosis","volume":"27","author":"Ramsay","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-021-02806-4_bib9","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1161\/CIRCULATIONAHA.115.016567","article-title":"Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis","volume":"132","author":"Fontana","year":"2015","journal-title":"Circulation"},{"key":"10.1007\/s12350-021-02806-4_bib10","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.004770","article-title":"Serial native T1 mapping to monitor cardiac response to treatment in light-chain amyloidosis","volume":"9","author":"Hur","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1007\/s12350-021-02806-4_bib11","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.jcmg.2020.03.010","article-title":"Native T1 mapping, extracellular volume mapping, and late gadolinium enhancement in cardiac amyloidosis: A meta-analysis","volume":"13","author":"Pan","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1007\/s12350-021-02806-4_bib12","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s12872-018-0952-8","article-title":"Diagnosis of cardiac amyloidosis: A systematic review on the role of imaging and biomarkers","volume":"18","author":"Kyriakou","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1007\/s12350-021-02806-4_bib13","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1007\/s12350-021-02806-4_bib14","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s12350-014-9901-9","article-title":"Quantitative interpretation of FDG PET\/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis","volume":"21","author":"Ahmadian","year":"2014","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-021-02806-4_bib15","unstructured":"Miller RJH, Cadet S, Pournazari P, Pope A, Kransdorf E, Hamilton MA et al. Quantitative Assessment of Cardiac Hypermetabolism and Perfusion for Diagnosis of Cardiac Sarcoidosis. J Nucl Cardiol 2020. (in press)."},{"key":"10.1007\/s12350-021-02806-4_bib16","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1002\/jmri.22753","article-title":"Myocardial T1 mapping with MRI: Comparison of look-locker and MOLLI sequences","volume":"34","author":"Nacif","year":"2011","journal-title":"J Magn Reson Imaging"},{"key":"10.1007\/s12350-021-02806-4_bib17","doi-asserted-by":"crossref","DOI":"10.1186\/1532-429X-17-S1-O27","article-title":"LGE-PSIR is an independent predictor of mortality in cardiac amyloidosis: a 250 patient prospective study","volume":"17","author":"Fontana","year":"2015","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1007\/s12350-021-02806-4_bib18","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1161\/hc0402.102975","article-title":"Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association","volume":"105","author":"Cerqueira","year":"2002","journal-title":"Circulation"},{"key":"10.1007\/s12350-021-02806-4_bib19","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/jmri.24116","article-title":"Validation of sub-segmental visual scoring for the quantification of ischemic and nonischemic myocardial fibrosis using late gadolinium enhancement MRI","volume":"38","author":"Fine","year":"2013","journal-title":"J Magn Reson Imaging"},{"key":"10.1007\/s12350-021-02806-4_bib20","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12968-016-0308-4","article-title":"Cardiac T1 mapping and extracellular volume (ECV) in clinical practice: A comprehensive review","volume":"18","author":"Haaf","year":"2016","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1007\/s12350-021-02806-4_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2288-8-1","article-title":"An administrative data merging solution for dealing with missing data in a clinical registry: Adaptation from ICD-9 to ICD-10","volume":"8","author":"Southern","year":"2008","journal-title":"BMC Med Res Methodol"},{"key":"10.1007\/s12350-021-02806-4_bib22","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jacc.2014.12.018","article-title":"2014 ACC\/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials","volume":"66","author":"Hicks","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s12350-021-02806-4_bib23","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1007\/s12350-021-02806-4_bib24","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"10.1007\/s12350-021-02806-4_bib25","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/jamacardio.2016.2839","article-title":"Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: Predicting survival for patients with ATTR cardiac amyloidosis","volume":"1","author":"Castano","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1007\/s12350-021-02806-4_bib26","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","article-title":"Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy","volume":"46","author":"Perugini","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s12350-021-02806-4_bib27","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s12350-019-01761-5","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2-Diagnostic criteria and appropriate utilization","volume":"27","author":"Dorbala","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-021-02806-4_bib28","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/S0735-1097(18)32230-7","article-title":"Suv quantification of 99mtc-Pyp imaging in Ttr-cardiac amyloidosis using a Czt camera: A new tool in the armamentarium","volume":"71","author":"Sikanderkhel","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s12350-021-02806-4_bib29","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3109\/13506129.2013.871250","article-title":"Bone scintigraphy with (99m)technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis","volume":"21","author":"Glaudemans","year":"2014","journal-title":"Amyloid"},{"issue":"5","key":"10.1007\/s12350-021-02806-4_bib30","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2967\/jnumed.120.247312","article-title":"Absolute quantitation of cardiac (99m)Tc-pyrophosphate using cadmium zinc telluride-based SPECT\/CT","volume":"62","author":"Dorbala","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1007\/s12350-021-02806-4_bib31","article-title":"Abstract 12230: Correlation of technetium pyrophosphate uptake with cardiac amyloid load, native T1, and extracellular volume in patients with transthyretin cardiac amyloidosis","volume":"140","author":"Morioka","year":"2019","journal-title":"Circulation"},{"key":"10.1007\/s12350-021-02806-4_bib32","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","article-title":"Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression","volume":"14","author":"Fontana","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1007\/s12350-021-02806-4_bib33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1136\/jcp.2004.017293","article-title":"Amyloid in the cardiovascular system: A review","volume":"58","author":"Kholov\u00e1","year":"2005","journal-title":"J Clin Pathol"},{"key":"10.1007\/s12350-021-02806-4_bib34","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jcmg.2018.02.006","article-title":"Native T1 and extracellular volume in transthyretin amyloidosis","volume":"12","author":"Martinez-Naharro","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1007\/s12350-021-02806-4_bib35","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jcmg.2015.10.027","article-title":"LGE provides incremental prognostic information over serum biomarkers in AL cardiac amyloidosis","volume":"9","author":"Boynton","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1007\/s12350-021-02806-4_bib36","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s12350-021-02806-4_bib37","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.amjmed.2015.05.039","article-title":"Noninvasive identification of ATTRwt cardiac amyloid: The re-emergence of nuclear cardiology","volume":"128","author":"Maurer","year":"2015","journal-title":"Am J Med"},{"key":"10.1007\/s12350-021-02806-4_bib38","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s00259-019-04290-y","article-title":"Detection of cardiac amyloidosis with (18)F-Florbetaben-PET\/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphy","volume":"46","author":"Kircher","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1007\/s12350-021-02806-4_bib39","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/13506129.2018.1552852","article-title":"A pilot study demonstrating cardiac uptake with 18F-florbetapir PET in AL amyloidosis patients with cardiac involvement","volume":"25","author":"Manwani","year":"2018","journal-title":"Amyloid"},{"key":"10.1007\/s12350-021-02806-4_bib40","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.jcmg.2020.02.025","article-title":"Improved quantification of cardiac amyloid burden in systemic light chain amyloidosis: Redefining early disease?","volume":"13","author":"Cuddy","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1007\/s12350-021-02806-4_bib41","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.119.010249","article-title":"Efficient 1-hour technetium-99 m pyrophosphate imaging protocol for the diagnosis of transthyretin cardiac amyloidosis","volume":"13","author":"Masri","year":"2020","journal-title":"Circ Cardiovasc Imaging"},{"issue":"6","key":"10.1007\/s12350-021-02806-4_bib42","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.jcmg.2019.10.015","article-title":"Low sensitivity of bone scintigraphy in detecting Phe64Leu mutation-related transthyretin cardiac amyloidosis","volume":"13","author":"Musumeci","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1007\/s12350-021-02806-4_bib43","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s12350-015-0261-x","article-title":"Serial scanning with technetium pyrophosphate ((99m)Tc-PYP) in advanced ATTR cardiac amyloidosis","volume":"23","author":"Casta\u00f1o","year":"2016","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-021-02806-4_bib44","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.jcmg.2020.03.020","article-title":"DPD quantification in cardiac amyloidosis: A novel imaging biomarker","volume":"13","author":"Scully","year":"2020","journal-title":"JACC Cardiovasc Imaging"}],"container-title":["Journal of Nuclear Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12350-021-02806-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12350-021-02806-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071358123005780?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071358123005780?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12350-021-02806-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T06:12:47Z","timestamp":1761027167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071358123005780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1071358123005780"],"URL":"https:\/\/doi.org\/10.1007\/s12350-021-02806-4","relation":{},"ISSN":["1071-3581"],"issn-type":[{"value":"1071-3581","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantitative technetium pyrophosphate and cardiovascular magnetic resonance in patients with suspected cardiac amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Nuclear Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s12350-021-02806-4","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 American Society of Nuclear Cardiology. Published by ELSEVIER INC. All rights reserved. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}